Middle East & Africa to dominate the Global Malaria Vaccine Market through 2028
Rising prevalence of
malaria are expected to drive the growth of Global Malaria Vaccine Market in
the forecast period, 2024-2028.
According to TechSci Research report, “Malaria
Vaccine Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028”,
Global Malaria Vaccine
Market is expected
to grow during the forecast period of 2024-2028. This can be ascribed to the increasing incidences of malaria, rising R&D activities,
and growing healthcare expenditure.
Global malaria
vaccine market is being driven by several factors, including increasing
investment in research and development of vaccines, the growing burden of
malaria in endemic regions, and the rising demand for effective malaria
prevention measures. The development of innovative vaccine technologies and
advances in understanding the complex nature of the malaria parasite are also driving
the growth of the market. In addition, government initiatives and partnerships
between public and private sectors to combat malaria are creating new
opportunities for vaccine manufacturers. Finally, the increasing awareness of
the importance of vaccination and the potential benefits of a malaria vaccine
are also contributing to the growth of the market. These factors are expected
to continue to drive the growth of the global malaria vaccine market in the
coming years.
Browse over XX market data Figures
spread through XX Pages and an in-depth TOC on "Malaria Vaccine Market.”
Global Malaria
Vaccine Market can be segmented by vaccine type, by route
of administration, and by region.
Based on vaccine
type, Global Malaria Vaccine Market can be divided into Pre-Erythrocytic,
Erythrocytic, Multi-antigen, and Others. The pre-erythrocytic segment is
expected to dominate the global malaria vaccine market in the coming years due
to the effectiveness of pre-erythrocytic vaccines in preventing malaria
infections. Pre-erythrocytic vaccines target the early stages of the malaria
parasite's life cycle, which is when it infects the liver and begins to
replicate. By targeting this stage of the infection, pre-erythrocytic vaccines
can prevent the parasite from causing symptoms and reduce the spread of the
disease. Additionally, pre-erythrocytic vaccines have shown promising results
in clinical trials and are in advanced stages of development. Several leading
vaccine candidates in the pre-erythrocytic segment are currently undergoing
clinical trials, indicating a significant focus on this area of the market.
Therefore, the pre-erythrocytic segment is expected to continue dominating the
global malaria vaccine market in the coming years.
Global Malaria
Vaccine Market is divided into North America, Europe, Asia Pacific, South
America and Middle East & Africa, based on region. The Middle East and
Africa region is expected to dominate the global malaria vaccine market in the
coming years due to the high prevalence of malaria in the region. Sub-Saharan
Africa, in particular, bears a significant burden of the disease. As a result,
there is a high demand for effective malaria prevention measures, including
vaccines, in this region. Additionally, several key market players, including
GlaxoSmithKline and Sanofi, have a strong presence in the region and are
actively involved in malaria vaccine research and development. Furthermore,
government initiatives aimed at combating malaria and increasing access to
healthcare in the region are expected to drive the growth of the market.
Therefore, the Middle East and Africa region is likely to dominate the global
malaria vaccine market in the coming years.
Major companies operating in Global Malaria Vaccine Market are:
- GlaxoSmithKline Plc.
- Novartis AG
- Takeda Pharmaceutical Company
- Sanaria Inc.
- Merck & Co.
- Johnson & Johnson
- Pfizer Inc.
- Serum Institute of India Private Limited
- Bharat Biotech International Limited
- Moderna Inc
Download Free Sample Report
Customers can also request
for 10% free customization on this report.
“Global malaria
vaccine market is rapidly evolving, with significant advancements in vaccine
technology and an increasing number of clinical trials for malaria vaccines.
The market is dominated by pre-erythrocytic vaccines, which target the early
stages of the malaria parasite's life cycle and have shown promising results in
clinical trials. There is also a growing focus on multi-stage vaccines that
target multiple stages of the parasite's life cycle, potentially leading to
increased efficacy. Technological advancements, such as the use of virus-like
particles and adjuvants, are also driving the development of more effective
vaccines. Additionally, there is a growing emphasis on the need for vaccines
that are effective against all strains of the parasite, including
drug-resistant strains. The increasing number of clinical trials and
partnerships between public and private sectors bodes well for the future of
the malaria vaccine market, with several promising vaccine candidates currently
in advanced stages of development.” said Mr. Karan Chechi, Research Director
with TechSci Research, a research based global management consulting firm.
“Malaria
Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2018-2028 Segmented By Vaccine Type (Pre-Erythrocytic, Erythrocytic,
Multi-antigen, Others), By Route of Administration (Intramuscular, Subcutaneous,
Intradermal, Others), Region and Competition”, has evaluated
the future growth potential of Global Malaria Vaccine Market and provides
statistics & information on market size, structure, and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Malaria Vaccine Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com